After treatment with 5 μM GSK‐650394 in AD model N2a‐APP cells for 48 h, it was found that the p‐FOXO3a/total FOXO3a ratio decreased significantly compared with the DMSO‐treated control group (Figure S8B), suggesting that there may be changes in APP metabolism. This evidence concerns the gene FOXO3 and Alzheimer disease.